1,4-dimethyldiethylenetriamine | 34066-96-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,4-dimethyldiethylenetriamine
• 英文别名: 1,4-dimethyl-1,4,7-triazaheptane；1,2-Ethanediamine, N-(2-aminoethyl)-N,N'-dimethyl-；N'-methyl-N'-[2-(methylamino)ethyl]ethane-1,2-diamine
• CAS: 34066-96-1
• 化学式: C₆H₁₇N₃
• mdl: MFCD09834484
• 分子量: 131.221
• InChiKey: BYWDOHJOAPKMOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,4-dimethyldiethylenetriamine 在 HCl 作用下， 以 盐酸 、 水 为溶剂， 生成
  参考文献：
  名称：

  Ventur, D.; Wieghardt, K.; Nuber, B., Zeitschrift fur Anorganische und Allgemeine Chemie

  摘要：

  DOI：

文献信息

• Sulfonamide compound
  申请人：Matsubara Koki

  公开号：US20090048223A1

  公开（公告）日：2009-02-19

  A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R 3 )(R 4 )— (R 3 and R 4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G 4 represents hydroxyl group (Y is a single group), or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.

  由以下化学式表示的化合物：[A代表含氮饱和环；m表示0到2的整数；n表示1到4的整数；G1代表氢原子、氯原子、羟基、烷氧基或氨基；G2代表卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；G3代表氢原子、卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；Y代表单键，或-C(R3)(R4)-（R3和R4代表氢原子、烷基或烷烯基，它们结合在一起形成饱和碳氢环基）；G4代表羟基（Y是单个基），或-N(R1)(R2)（R1和R2代表氢原子、烷基、芳基、烯基、炔基、饱和杂环基、烷基磺酰基、酰基或胺基）；G5是A的环构成碳原子上的取代基，代表氢原子、氟原子或烷基]或其盐、或作为前药的衍生物，其强力抑制Rho激酶。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS AND NEUROLOGICAL DISEASES
  申请人：Kandula Mahesh

  公开号：US20150141513A1

  公开（公告）日：2015-05-21

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, Psychiatric/neurodegenerative disorders, ADHD, Psychiatric/neurodegenerative disorders, Depersonalization disorder, Cognitive enhancement, Fatigue, Post-chemotherapy cognitive impairment and weight loss.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包含公式I化合物的有效量的药物组合物，以及用于治疗神经退行性疾病和神经疾病的方法，可以制备成口服、颊内、直肠、局部、经皮、经粘膜、静脉内、肠外给药、糖浆或注射剂。这些组合物可用于治疗嗜睡症、轮班工作睡眠障碍，并作为阻塞性睡眠呼吸暂停/减少症、嗜睡症（如特发性嗜睡症）、精神/神经退行性疾病、注意力缺陷多动障碍、精神/神经退行性疾病、人格解体障碍、认知增强、疲劳、化疗后认知障碍和体重减轻的辅助治疗。
• The influence of different n-substituted diethylenetriamine ligands on the aggregation of copper(II) monoacetato complexes
  作者：Fernande D. Rochon、Robert Melanson、Marius Andruh

  DOI：10.1016/0277-5387(96)00017-4

  日期：1996.6

  differences between the three perchlorate compounds arise in the coordination modes exhibited by the acetato groups: monodentate terminal, asymmetric chelating and syn-anti bridging. In 1 the structure consists of discrete ions, containing terminal monodentate acetato ligands. Compounds 2 contains discrete cations interconnected through hydrogen bonds between the acetato ligand and the tridentate amine

  具有不同结构特征的复合物选自Cu的反应形成2（MeCOO）4（H 2 O）2与各种Ñ二亚乙基三甲基衍生物（二烯）在CLO的存在下4 -或PF 6 - 。获得了四种化合物并通过晶体学方法进行了研究：[Cu（Me 5 dien）（MeCOO）（H 2 O）]（ClO 4）（1），[Cu（1,4-Me 2 dien）（MeCOO）]（ ClO 4）（2），[Cu（1,1-Me 2 dien）（MeCOO）] n（ClO 4）n（ 3）和[Cu（1,1-Me 2 dien）（MeCOO）] n（PF 6） n（ 4）。三种高氯酸盐化合物之间的差异是由乙酰基基团表现出的配位模式引起的：单齿末端，不对称螯合和顺-反桥联。在图1中，结构由离散离子组成，包含末端单齿乙酰基配体。化合物2包含离散的阳离子，该阳离子通过乙酰基配体和三齿胺之间的氢键相互连接，化合物3是聚合的，通过乙酰基桥形成无限链。化合物4具有
• Synthesis of tridentate amine Pt(II) complexes and study of their reactions with purine and pyrimidine bases
  作者：Fernande D. Rochon、Guylaine Laperrière

  DOI：10.1139/v94-155

  日期：1994.5.1

  Complexes of the type [Pt(L)X] where L is a tridentate N ligand and X = Cl or I, were synthesized and characterized. Three of the ligands are N-derivatives of diethylenetriamine, (2-aminoethyl)(N-dimethyl-2-aminoethyl)amine, (2-aminoethyl)(N-diethyl-2-aminoethyl)amine, and (2-aminoethyl)(N-methyl-2-aminoethyl)N-methylamine. The other two ligands are di(3-amino-propyl)amine and (2-aminoethyl)(3-aminopropyl)amine

  合成并表征了 [Pt(L)X] 类型的配合物，其中 L 是三齿 N 配体且 X = Cl 或 I。其中三个配体是二亚乙基三胺的 N-衍生物、(2-氨基乙基)(N-二甲基-2-氨基乙基)胺、(2-氨基乙基)(N-二乙基-2-氨基乙基)胺和(2-氨基乙基)( N-甲基-2-氨基乙基)N-甲胺。另外两个配体是二(3-氨基-丙基)胺和(2-氨基乙基)(3-氨基丙基)胺。开发了一种通过胺与 K2[PtCl4] 直接反应合成氯配合物的新方法。通过核磁共振技术研究了这五种化合物与几种嘌呤和嘧啶碱的反应。含有两个五元螯合物的 Pt(II) 配合物被证明比含有两个六元环的复合物更具反应性，而含有一种五元螯合物和一种六元螯合物的配合物则表现出中等反应性。对于二亚乙基三胺衍生物，含有在同一末端 N 原子上具有两个烷基的配体的配合物...
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET D'UNE INFLAMMATION
  申请人：KANDULA MAHESH

  公开号：WO2014115098A1

  公开（公告）日：2014-07-31

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing neurological diseases and inflammation, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, neurological diseases and inflammation, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, asthma, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications.

  该发明涉及具有化学式I或其药用可接受的盐的化合物，以及其多型、溶剂合物、对映体、立体异构体和水合物。包括化学式I化合物的有效量的药物组合物；以及用于治疗或预防神经系统疾病和炎症、神经系统疾病、过敏、呼吸系统疾病或炎症性疾病的方法，可以制备用于口服、颊内、直肠、局部、经皮、经粘膜、静脉内、肠道、糖浆或注射的药物组合物。这些组合物可以用于治疗肌肉障碍、神经系统疾病和炎症、痉挛、神经病性疼痛、纤维肌痛、帕金森病、过敏、哮喘、慢性阻塞性肺病、过敏性鼻炎、头痛、慢性疼痛、亚慢性疼痛和局部疼痛或其相关并发症的治疗。

表征谱图